Struggling to control high BP? Learn about resistant hypertension, its causes, and expert-approved ways to manage it. Get ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary endpoints in the BaxHTN Phase III trial, effectively lowering blood pressure ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

In addition to taking medication, paying attention to these habits can help maintain healthy blood pressure levels..resistant ...

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

AstraZeneca AZN reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

In a new clinical practice guideline, the Endocrine Society advises universal screening of those with hypertension by ...